The High-Risk Human Papillomavirus Type Influences the Tissue Microenvironment in Cervical Intraepithelial Neoplasia Grade 2
暂无分享,去创建一个
A. Rajesh | M. Hibma | R. A. van der Griend | B. Simcock | Carrie R. Innes | Mayumi Saito | Peter Fitzgerald | Peter Sykes
[1] J. Califano,et al. Human papillomavirus E5 suppresses immunity via inhibition of the immunoproteasome and STING pathway , 2023, Cell reports.
[2] Susan M. Schlenner,et al. Regulatory T‐cell stability and functional plasticity in health and disease , 2022, Immunology and cell biology.
[3] A. Rajesh,et al. Blimp-1 is a prognostic indicator for progression of cervical intraepithelial neoplasia grade 2 , 2022, Journal of Cancer Research and Clinical Oncology.
[4] R. Bekkers,et al. Importance of the Immune Microenvironment in the Spontaneous Regression of Cervical Squamous Intraepithelial Lesions (cSIL) and Implications for Immunotherapy , 2022, Journal of clinical medicine.
[5] L. Sadler,et al. Predicting regression of cervical intraepithelial neoplasia grade 2 in women under 25 years. , 2021, American journal of obstetrics and gynecology.
[6] Bin Yu,et al. Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy , 2021, Journal of Hematology & Oncology.
[7] A. Karube,et al. Progression of cervical intraepithelial neoplasia grade 2 lesions among Japanese women harboring different genotype categories of high-risk human papillomaviruses , 2021, Journal of rural medicine : JRM.
[8] J. Taube,et al. Characterization of the tumor immune microenvironment in human papillomavirus-positive and -negative head and neck squamous cell carcinomas , 2020, Cancer Immunology, Immunotherapy.
[9] K. Simpson,et al. Loss of HPV type 16 E7 restores cGAS-STING responses in human papilloma virus-positive oropharyngeal squamous cell carcinomas cells. , 2020, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.
[10] A. Orr,et al. Human Papillomavirus 16 E5 Inhibits Interferon Signaling and Supports Episomal Viral Maintenance , 2019, Journal of Virology.
[11] Akintunde Akinleye,et al. Immune checkpoint inhibitors of PD-L1 as cancer therapeutics , 2019, Journal of Hematology & Oncology.
[12] L. Villa,et al. Indoleamine 2,3‐dioxygenase and tryptophan 2,3‐dioxygenase expression in HPV infection, SILs, and cervical cancer , 2019, Cancer cytopathology.
[13] L. Sadler,et al. Changes in human papillomavirus genotypes associated with cervical intraepithelial neoplasia grade 2 lesions in a cohort of young women (2013–2016) , 2018, Papillomavirus research.
[14] G. Kenter,et al. Indoleamine 2,3-Dioxygenase Expression Pattern in the Tumor Microenvironment Predicts Clinical Outcome in Early Stage Cervical Cancer , 2018, Front. Immunol..
[15] M. Kyrgiou,et al. Clinical course of untreated cervical intraepithelial neoplasia grade 2 under active surveillance: systematic review and meta-analysis , 2018, British Medical Journal.
[16] J. Doorbar. Host control of human papillomavirus infection and disease. , 2017, Best practice & research. Clinical obstetrics & gynaecology.
[17] L. Sadler,et al. Observational Management of CIN 2 in Young Women: A Prospective Multicenter Trial , 2016, Journal of lower genital tract disease.
[18] Cara C. Schafer,et al. Indoleamine 2,3-dioxygenase regulates anti-tumor immunity in lung cancer by metabolic reprogramming of immune cells in the tumor microenvironment , 2016, Oncotarget.
[19] J. Doorbar,et al. Human papillomavirus molecular biology and disease association , 2015, Reviews in medical virology.
[20] J. Renauld,et al. Extensive Profiling of the Expression of the Indoleamine 2,3-Dioxygenase 1 Protein in Normal and Tumoral Human Tissues , 2014, Cancer Immunology Research.
[21] A. Blumenthal,et al. Indoleamine 2,3-dioxygenase Activity Contributes to Local Immune Suppression in the Skin Expressing Human Papillomavirus Oncoprotein E7 , 2013, The Journal of investigative dermatology.
[22] M. Henry,et al. The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: Background and Consensus Recommendations From the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology , 2012, Archives of pathology & laboratory medicine.
[23] Yong-Yeon Cho,et al. Human papillomavirus 16E6 suppresses major histocompatibility complex class I by upregulating lymphotoxin expression in human cervical cancer cells. , 2011, Biochemical and biophysical research communications.
[24] K. Münger,et al. Human papillomavirus E7 oncoprotein induces KDM6A and KDM6B histone demethylase expression and causes epigenetic reprogramming , 2011, Proceedings of the National Academy of Sciences.
[25] T. Iftner,et al. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. , 2010, Journal of the National Cancer Institute.
[26] G. Visner,et al. Reduced Cytotoxic Function of Effector CD8+ T Cells Is Responsible for Indoleamine 2,3-Dioxygenase-Dependent Immune Suppression1 , 2009, The Journal of Immunology.
[27] P. Lambert,et al. Human Papillomavirus Type 16 E1∧E4-Induced G2 Arrest Is Associated with Cytoplasmic Retention of Active Cdk1/Cyclin B1 Complexes , 2005, Journal of Virology.
[28] P. Beard,et al. E1∧E4 Protein of Human Papillomavirus Type 16 Associates with Mitochondria , 2004, Journal of Virology.
[29] J. Doorbar,et al. Depletion of Langerhans Cells in Human Papillomavirus Type 16-Infected Skin Is Associated with E6-Mediated Down Regulation of E-Cadherin , 2003, Journal of Virology.
[30] B. Quade,et al. Ki-67, Cyclin E, and p16 INK4 Are Complimentary Surrogate Biomarkers for Human Papilloma Virus-Related Cervical Neoplasia , 2001, The American journal of surgical pathology.
[31] Fan Zhang,et al. Cyclooxygenase-2 is overexpressed in human cervical cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[32] D. Munn,et al. Inhibition of T Cell Proliferation by Macrophage Tryptophan Catabolism , 1999, The Journal of experimental medicine.
[33] D. Munn,et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. , 1998, Science.
[34] S. Napthine,et al. Characterization of events during the late stages of HPV16 infection in vivo using high-affinity synthetic Fabs to E4. , 1997, Virology.
[35] humAn cArcinogens,et al. iArc monogrAphs on the evAluAtion oF cArcinogenic risks to humAns , 2012 .